Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL
The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.
Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis
Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.
Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC
Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.
Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting
Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma
The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.
3 Things You Should Know About Targeting NRG1 and Rare Drivers in Pancreatic Cancer
Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.
